MEI PharmaMEIP
MEIP
About: MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Employees: 28
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,700% more call options, than puts
Call options by funds: $28K | Put options by funds: $1K
0.53% less ownership
Funds ownership: 40.61% [Q4 2024] → 40.08% (-0.53%) [Q1 2025]
3% less funds holding
Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]
12% less capital invested
Capital invested by funds: $6.65M [Q4 2024] → $5.85M (-$807K) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for MEIP.
Financial journalist opinion
Neutral
Business Wire
1 month ago
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.
Neutral
Business Wire
4 months ago
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its st.
Neutral
Business Wire
7 months ago
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders.
Neutral
Business Wire
8 months ago
MEI Pharma Reports Fiscal Year End 2024 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and.
Neutral
Business Wire
10 months ago
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if com.
Neutral
Business Wire
10 months ago
MEI Pharma to Consider Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. In order to best preserve the Company.
Positive
InvestorPlace
11 months ago
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Neutral
Business Wire
1 year ago
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible violations of state laws. If you own MEI Pharma stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy.
Neutral
Business Wire
1 year ago
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events. “Over the past several months, MEI has received encouraging clinical data for voruciclib and ME-344 supporting the further development of these programs,” said David Urso,.
Neutral
Business Wire
1 year ago
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company's Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additiona.
Charts implemented using Lightweight Charts™